A long-term strategy
8.18. In the event of a pandemic the speed with
which a vaccine can be prepared, manufactured and distributed
will be crucial. We therefore make the following recommendations:
- The Government should follow the example of the
United States in making a major investment in developing new vaccine
production techniques. The industry has been too conservative
in relying on tried and tested methods; it is time for the Government
to show leadership;
- The Government should explore mechanisms to encourage
the free exchange of proprietary technology between vaccine manufacturers;
- With a view to promoting public health, the Government
should continue to encourage take-up of the annual "flu jab"
by at-risk groups. However, we do not believe that the corresponding
increase in manufacturing capacity will be sufficient to meet
the challenges of a pandemic. The Government should explore other
incentives to the industry to develop surge capacity;
- In the event of a global pandemic, inequitable
distribution of limited vaccine stocks could have serious implications
for international relations. We therefore urge the Government,
in conjunction with United Nations agencies, to examine ways to
develop vaccine manufacturing capacity globally;
- We welcome the initiative of the European Medicines
Evaluation Agency in developing a "mock-up" dossier
for a pandemic vaccine. We recommend that the Government invest
in one or more "mock-up" dossiers with a view to removing
the regulatory barriers to a new vaccine.
8.19. We recommend that the Government fund further
research on alternative treatments for pandemic influenza. This
should include a full assessment of the risks and benefits of
fractionation. If such risk analysis is left until a pandemic
outbreak it will be too late.
8.20. We agree with Professor Menon that a pandemic
would present a unique opportunity for detailed research into
the effectiveness of treatments, immune responses, the causes
of mortality, and related issues, which could offer enormous long-term
health benefits. The Government have a duty to facilitate such
research, which will not be possible without advance ethical clearance,
rapid access to funding, and the suspension of various legal and
regulatory requirements.
8.21. We therefore recommend that the Government
initiate a public dialogue on the regulatory barriers to research
in the event of a pandemic. We believe the public would support
this research if its benefits were properly explained.